MedTrace Logo

Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status

NCT04169178 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2020-05-01

No results posted yet for this study

Summary

A mutilpe-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX55 in patients with advanced solid tumors overexpressing/Mutation/Amplification cMET after failure of standard of care.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

HLX55

A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)

Sponsors & Collaborators

  • Henlix, Inc

    lead INDUSTRY

Principal Investigators

  • Tsu-Yi Chao, MD. PhD. · Shuang Ho Hospital,Ministry of Health and Welfare, Taipei, Taiwan

  • Ching-Liang Ho, MD · Tri-Service General Hospital, Taipei, Taiwan

  • Wu-Chou Su, MD. PhD. · National Cheng Kung University Hospital, Tainan, Taiwan

  • Chia-Lun Chang, MD · Taipei Municipal Wanfang Hospital, Taipei, Taiwan

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-03
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04169178 on ClinicalTrials.gov